| | Included trial | Publication language | Study design and investi-
gational sites | Type of cancer | No.of participants (male/female;age years) | Intervention | Outcome index | Intergroup difference | | | | | | Experimental | Control | Experimental | Control | | |
| | Chen 2012 [8] | Chinese | RCT,Single cencer;China | Primary Liver Cancer | 38/11;44.7 | 41/8;47.1 | Danshen formulae | Vinorelbine +Cisplatin(NP)+Placebo (Huangqi, Huangjing, Jiaogulan, Lingzhi, Cangzhu, Nvzhenzi, Huanglian et al.) | 1.RR; 2.Survival rate;3.Improvement of symptoms | 1,2.P>0.05; 3<0.05 | | Gong 2018 [9] | English | RCT,Single cencer;China | Non-small cell lung cancer (NSCLC) | 80/51;40-78 | 66/42;41-80 | Vinorelbine +Cisplatin(NP)+Danshen formulae | Platinum-based therapy +Placebo (Jiegeng, Xingren, Yuxingcao, Ziwan, Kuandong, Zhebeimu, Banxia, Hexiancao, Shengdiyu, Huangqin, Dongguazi, Chenpi, Zhuru et al.) | 1.Survival Rates;2.MST | 1,2.P<0.05 | | Guo 2017 [10] | English | RCT, Multi-cente;China | NSCLC | 20/9;38-77 | 28/4;38-77 | Platinum-based therapy +Danshen formulae | Radiotherapy | 1.RR;2.Nausea; 3.Vomit;4.QOL; 5.Mildgastric/abdominal heaviness | 1,2,3,5.P<0.05;4.P>0.05 | | Lan 2003 [11] | English | RCT,Single cencer;China | Lung cancer | 16/10;70-77 | 13/8;70-79 | Radiotherapy+Danshen formulae | DAP | RR(1.Short-term effect;2. Long-term effect) | 1.P>0.052.P<0.01 | | Li 2017 [12] | Chinese | RCT,Single cencer;China | Leukemia | 10/15;(35.42±15.13 | 13/12;37.97±13.45 | DAP+Jiedu Huayu Fang | Radiotherapy+placebo (Xuanshen,Yiyiren, Chenqianzi, Yinchen, Difuzi, Chuanwu, Ganjiang, Rougui, Wuzhuyu, Xiangfuzi, Chenpi, Shanzha, Laifuzi, Sanqi, Ruxiang, Yujin et al.) | 1.RR(CR+PR);2.Leukopenia; 3.Platelet(PLT)decreased; 4.Hemoglobin(HGB)decreased | 1,3,4.P<0.05;2.P>0.05 | | Mok 2007 [13] | English | RCT,Single cencer;China | Breast or colon cancer | 5/50;32-75 | 6/50;39-72 | Radiotherapy+Danshen formulae | Paclitaxel Injection+Cisplatin Injection | 1.HGB decreas
-ed;2.Leukopenia;3.Neutropenia; 4.Thrombocytopenia;5.Nausea; 6.QOL | 1-4,P>0.05;5,6.P<0.05 | | Shen 2017 [14] | Chinese | RCT,Single cencer;China | NSCLC | 22/21;57.2 ±7.3 | 23/20;56.8±7.5 | Paclitaxel Injection+Cisplatin Injection+Zilongjin tablet | 3-DCRT | 1.RR;2.Leucopenia;3.Erythropenia; 4.Thrombocytopenia;5.Nausea;6.DCR | 1,2,3,5,6.P<0.05;4.P>0.05 | | Wang 2010 [15] | Chinese | RCT,Single cencer;China | Primary liver cancer | 28/13;32-68 | 25/14;33-67 | 3-DCRT+Aixiao Aixiao Ruanganjian | UFTM/FMV | 1.RR;2.Leucopenia;3.Platelet descend; 4.Hemoglobin reduction.5.T-cells; 6.Survival rate;7.Nausea | 1-7.P<0.05 | | Wen 1996 [16] | Chinese | RCT,Single cencer;China | Gastric cancer | 8/3;47-73 | 5/3;50-69 | UFTM/FMV+Jianpi Kangai mixtures | DA/HA/IA | 1.RR | 1.P<0.05 | | Xu 2004 [17] | Chinese | RCT,Single cencer;China | Acute myleoid leukemia | 19/11;11-65 | 20/10;12-64 | DA/HA/IA+Danshen formulae | Radiotherapy+Placebo (TizisheN, huangbai, Baizhu, Gouqi, Huang jing, Tiandong, Maidong, Xuan shen, Nvzhenzi, Hanliancao, Pugonging, Banzhilian, Baihuasheshecao, Xiaoji et al.) | 1.RR;2.Aminotransferase | 1,2.P<0.05 | | Yan 1995 [18] | Chinese | RCT,Single cencer;China | Acute leukemia | 16/19;14-60 | 18/17;17-60 | Radiotherapy+Danshen formulae | General symptomatic treatment+Fufang Banmao Capsule | 1.RR;2.Survival rate | 1.P<0.05;2.P<0.01 | | Zeng 2015 [19] | Chinese | RCT,Single cencer;China | Liver cancer | 20/4;52.96±7.14 | 19/5;53.95±10.25 | General symptomatic treatment+Fuzhengkangai decoction | DDP+VP-16 | 1.RR;2.ALT;3.AST;4.GGT;5.AFP;6.CR+PR; 7. CR+PR+NC; 8.Survival rates; 9.Nausea;10.Vomiting | 1,4,7.P<0.05; 2,3.P<; 5,6,8,9,10.P>0.05 | Zhang 2013
[20] | Chinese | RCT,Single cencer;China | NSCLC | Total:48/30;55±2.1 | DDP+VP-16d123+Xidan Tang | Vinorelbine +Cisplatin(NP)+Placebo (Huangqi, Huangjing, Jiaogulan, Lingzhi, Cangzhu, Nvzhenzi, Huanglian et al.) | 1.Survival rate;2.Nausea, vomiting and loss of appetite | 1.P<0.05; 2.P>0.05 |
|
|
